Small-Angle X-ray Scattering for Pharmaceutical Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Small-Angle X-ray Scattering for Pharmaceutical Applications
The author describes the development of small-angle X-ray scattering and analyzes its advantages in the characterization of drug-delivery systems and large molecules. This article is part of a special Analytical Technology issue.


Pharmaceutical Technology
Volume 34, pp. s32-s37

References

1. Fifty Years of X-ray Diffraction, P.P. Ewald, Ed. (A. Oosthoek's Uitgeversmaatschappij, Utrecht, 1962).

2. M. Lambert, Acta Crystallogr. 57 (1), 1–3 (2001).

3. J. Schurz, Colloid Polym. Sci. 273 (10), 994–995 (1995).

4. Small Angle X-ray Scattering, O. Glatter and O. Kratky, Eds. (Academic Press, London, 1982) 4f.

5. H. Schnablegger and Y. Singh, "A Practical Guide to SAXS," (Anton Paar, Graz, Austria, 2006).

6. J. Lake, Acta Crystallogr. 23 (2), 191 (1967).

7. G.R. Strobl, Acta Crystallogr. A 26 (3), 367–375 (1970).

8. M. Soliman, B.J. Jungnickel, and E. Meister, Acta Crystallogr., A, Found. 54 (5), 675–681 (1998).

9. C. Jeffries et al., J. Mol. Biol. 377 (4), 1186–1199 (2008).

10. H. Schnablegger, "Is Smearing An Issue?" (Anton Paar Graz, Austria, 2007).

11. M. Muthukumar, C.K. Ober, and E.L. Thomas, Science 277 (5330), 1225–1232 (1997).

12. G.M. Whitesides, J.P. Mathias, and C.T. Seto, Science 254 (5036), 1312–1319 (1991).

13. G.M. Whitesides and B. Crzybowski, Science 295 (5552), 2418–2421 (2002).

14. A.M. Edwards et al., Nat. Struct. Biol. 7 (11), 970–972 (2000).

15. R.F. Fischetti et al., J. Synchrotron Radiat. 10 (5), 398–404 (2003).

16. M. Hirai et al., J. Synchrotron Radiat. 9 (4), 202–205 (2002).

17. D.M. Tiede, R. Zhang, and S. Seifert, Biochemistry 41, 6605–6614 (2002).

18. R. Zhang, P. Thiyagarajan, and D.M. Tiede, J. Appl. Crystallogr. 33 (3), 565–568 (2000).

19. D.I. Svergun and M.H.J. Koch, Rep. Prog. Phys. 66 (10), 1735–1782 (2003).

20. J. Trewhella and J.K. Krueger, Methods Mol. Biol. 173, 137–159 (2002).

21. P. Chacon et al., Biophys. J. 74 (6), 2760–2775 (1998).

22. P. Chacon et al., J. Mol. Biol. 299 (5), 1289–1302 (2000).

23. D. Svergun, Biophys. J. 76 (6), 2879–2886 (1999), erratum in 77, (5), 2896–2896 (1999).

24. G. Fritz, A. Bergmann, and O. Glatter, J. Chem. Phys. 113 (21), 9733–9740 (2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here